Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.. Athira, which went public in 2020, is ...

Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental ...

However, Athira said ADAS-Cog11 and ADCS-ADL23 “directionally favored fosgonimeton treatment,” with a nonsignificant difference of 0.70 on the cognition scale and 0.67 on the function score.

Just a couple of weeks after announcing that its Alzheimer’s disease candidate fosgonimeton failed to beat placebo in a phase 2/3 trial, Athira is laying off 70% of its staff and saying goodbye ...

Athira Pharma said that Alzheimer’s patients who received its experimental injection fosgonimeton did not decline at a significantly slower rate than patients who received a placebo injection.

Athira Pharma, Inc. Reporting of Topline Results Targeted by End of Third Quarter 2024. Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October ...

Athira Pharma, Inc. ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and ...

A high-level overview of Athira Pharma, Inc. (ATHA) stock. View (ATHA) real-time stock price, chart, news, analysis, analyst reviews and more.

Athira Pharma (NASDAQ:ATHA) shares fell over 75% after the company said fosgonimeton, its experimental therapy for Alzheimer's disease, failed in a Phase 2/3 trial, prompting at least two Wall ...

Athira conducted the first-in-human Phase 1 (NCT 06432647) double-blind, placebo-controlled clinical trial that enrolled 80 healthy volunteers to evaluate single and multiple oral ascending doses ...

Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.

From what we can see, insiders were net buyers in Athira Pharma, Inc.'s (NASDAQ:ATHA ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it ...